Study on the Impact of Piperacillin Tazobactam Sodium Combined with Moxifloxacin on the Improvement of Clinical Symptoms in Elderly Patients with Mild Pneumonia
Objective To explore the therapeutic value of piperacillin tazobactam sodium combined with moxifloxacin in elderly patients with mild pneumonia.Methods 80 elderly patients with mild pneumonia admitted to Luoyang Central Hospital from January 2023 to December 2023 were selected as the research subjects.According to the random number table method,they were divided into two groups.The control group of 40 patients was treated with moxifloxacin,and the experimental group of 40 patients was treated with piperacillin tazobactam sodium combined with moxifloxacin.The treatment effects,clinical symptoms(shortness of breath,lung rales,and cough)improvement,inflammatory factors[Interleukin-6(IL-6),Tumor Necrosis Factor(TNF-α),and C-reactive protein(CRP)]levels,lung function indicators[Forced Vital Capacity(FVC),Forced Expiratory Volume in the first second(FEV1),and the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity(FEV1/FVC)],and adverse reactions were compared between the two groups.Results The effective rate of treatment in the experimental group was higher than that in the control group,and the difference was statistically significant(P＜0.05).The time for the relief of cough,lung rales,and shortness of breath in the experimental group was shorter than that in the control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of inflammatory factors in both groups decreased,and the lung function indicators increased.Among them,the level of inflammatory factors in the experimental group was lower than that in the control group,and the lung function indicators were higher than those in the control group.The difference was statistically significant(P＜0.05).The incidence of adverse reactions in the two groups was not statistically significant(P＞0.05).Conclusion The treatment of elderly patients with mild pneumonia using piperacillin tazobactam sodium combined with moxifloxacin can improve the treatment effect,shorten the time for the improvement of clinical symptoms,reduce the level of inflammatory factors,improve the level of lung function indicators,and is safe and reliable,and is worth using in clinical practice.
国家科技期刊平台
NSTL
万方数据
